CTI BIOPHARMA CORP (CTIC)

US12648L6011 - Common Stock

9.09  0 (0%)

After market: 9.09 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CTI BIOPHARMA CORP

NASDAQ:CTIC (6/23/2023, 7:00:00 PM)

After market: 9.09 0 (0%)

9.09

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.20B
Shares
PEN/A
Fwd PE22.47
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CTIC Daily chart

Company Profile

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. The company is headquartered in Seattle, Washington and currently employs 128 full-time employees. The firm is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). The company is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). The company also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. The company is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Company Info

CTI BIOPHARMA CORP

3101 Western Ave Ste 800

Seattle WASHINGTON 98121

P: 12062827100.0

CEO: Adam R. Craig

Employees: 128

Website: https://www.ctibiopharma.com/

CTIC News

News Image6 months ago - Investor's Business DailyIncyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer.

News Image9 months ago - Swedish Orphan Biovitrum ABSobi completes acquisition of CTI BioPharma Corp.

/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (SobiĀ®) (STO:SOBI) and CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) announced today the completion of the...

News Image9 months ago - Swedish Orphan Biovitrum ABSobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

/PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (SobiĀ®) (STO: SOBI) announced today that it has, through its indirect wholly owned subsidiary Cleopatra...

News Image10 months ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECT, NATI, CTIC, USX

/PRNewswire/ --Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image10 months ago - Kahn Swick & Foti, LLCCTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC
News Image10 months ago - CTI BioPharma Corp.CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

/PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel...

CTIC Twits

Here you can normally see the latest stock twits on CTIC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example